Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
ConclusionsIn this small, self-selected cohort, the results indicate a therapeutic effect of monoclonal antibodies targeting the CRGP pathway in chronic migraine prevention after treatment termination up to 12 weeks.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research